BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22451559)

  • 1. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging.
    Bronstein Y; Ng CS; Rohren E; Ross MI; Lee JE; Cormier J; Johnson VE; Hwu WJ
    AJR Am J Roentgenol; 2012 Apr; 198(4):902-8. PubMed ID: 22451559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
    Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
    Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
    Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT].
    Dellestable P; Granel-Brocard F; Rat AC; Olivier P; Régent D; Schmutz JL
    Ann Dermatol Venereol; 2011 May; 138(5):377-83. PubMed ID: 21570561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
    Niederkohr RD; Rosenberg J; Shabo G; Quon A
    Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
    Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
    J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Body [
    Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
    Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
    Pfluger T; Melzer HI; Schneider V; La Fougere C; Coppenrath E; Berking C; Bartenstein P; Weiss M
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):822-31. PubMed ID: 21210112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer.
    Manohar K; Mittal BR; Bhoil A; Bhattacharya A; Singh G
    Nucl Med Commun; 2013 Jun; 34(6):557-61. PubMed ID: 23549551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
    Gulec SA; Faries MB; Lee CC; Kirgan D; Glass C; Morton DL; Essner R
    Clin Nucl Med; 2003 Dec; 28(12):961-5. PubMed ID: 14663316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
    Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
    Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
    J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
    Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
    Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.